Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HRS 8080

Drug Profile

HRS 8080

Alternative Names: HRS-8080

Latest Information Update: 03 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shandong Suncadia Medicine
  • Developer Jiangsu Hengrui Medicine Co.; Shandong Suncadia Medicine
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Selective estrogen receptor degraders
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Breast cancer

Most Recent Events

  • 03 Jul 2024 Phase-I/II clinical trials in Breast cancer (In adults, In the elderly, Metastatic disease, Late-stage disease, Combination therapy, Inoperable/Unresectable, Second-line therapy or greater) (PO), prior to July 2024 (NCT06222879) (Jiangsu Hengrui Medicine pipeline, July 2024)
  • 25 Jan 2024 Shandong Suncadia Medicine plans a phase I/II trial for Breast cancer (Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy, Combination therapy) in January 2024 (PO) (NCT06222879)
  • 20 Dec 2023 Phase-I/II clinical trials in Breast cancer (Metastatic disease, Inoperable/Unresectable, Combination therapy, Late-stage disease) in China (PO) (NCT06167694)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top